APCCC 2019

APCCC in general

In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic. Further developments such as novel next-generation imaging methods, biomarkers, molecular characterization and genetics lead to many areas with open questions and lack or low level of evidence. 

The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum for discussion and debates on current management options for men with advanced prostate cancer in these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions and debates, summarizing and conceptualizing the available literature and evidence.

The conference concludes with voting by the panel on pre-defined consensus questions, targeting areas of clinical relevance. Following the conference a manuscript with containing the expert recommendations is published in a peer reviewed journal (2015 Annals of Oncology, 2017 European Urology).

Aims of APCCC

• Provide an update on the current standard of advanced prostate cancer management with a focus on situations with no high level evidence for a specific treatment option.
• Advanced prostate cancer is defined by APCCC as locally advanced disease and men with biochemical recurrence or metastatic disease.
• Program is highly educational, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary prostate cancer experts.
• The entire conference is focused on “knowledge translation” by summarising and conceptualising the current standards of advanced prostate cancer management and disseminating the results of the consensus discussions and votings.
• The conference will culminate with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. The process of the conference and the development of the questions have been described in detail (Ref APCCC 2015 und APCCC 2017).
• Participants will be able to attend the two days of the discussions as well as the voting of the panellists as part of the conference.
• The consensus summary is published after the meeting in a high impact medical journal.
• Attendees will be able to interact with panel members, facilitating and encouraging international collaboration.

Preview of the APCCC 2019 - Interview with Silke Gillessen

Silke Gillessen, in conversation with Alicia Morgans provides an overview of many of the changes we are experiencing in clinical practice since the 2017 APCCC. They touch upon the new data that is driving change in clinical practice and some unanswered questions that have arisen and will be discussed in the upcoming 2019 Advanced Prostate Cancer Consensus Conference (APCCC 2019).  The next APCCC is scheduled for August 29 - 31, 2019 in Basel, Switzerland. These topics include the many new trials, the approval of apalutamide by FDA and anticipated approvals of other drugs in M0 CRPC, as well as data of novel imaging methods.  The APCCC provides an update on the current standard of advanced prostate cancer management and a global discussion amongst attendees on questions that occur in daily clinical practice for which there is limited evidence-based data. (Source: www.urotoday.com, 11 April 2018)

Please click here to see "Preview of the APCCC 2019 - Interview with Silke Gillessen"

Consensus 2017

The consensus summary is available and published in European Urology. Please find it also here for download.

Please note that detailed results of the voting of the consensus questions can be found here: Part A and Part B.

Evaluation of APCCC 2017
Please find it here for download. 

Impressions of APCCC 2017

Consensus 2015

The consensus summary is available and published in Annals of Oncology. Please find it also here for download

Please note that detailed voting results as well as conflict of interest statements of all panel members are available at Annals of Oncology as supplemental material.  

Evaluation of APCCC 2015
Please find it here for download